StockData

Abeona Therapeutics vs Lexicon Pharmaceuticals

ABEO and LXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABEO and LXRX compare

Lexicon Pharmaceuticals is the larger company, worth 5.3 times as much as Abeona Therapeutics ($792M against $149M).

Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −246% at Abeona Therapeutics.

Abeona Therapeutics scores higher on the StockData Score (8 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABEOLXRX
Size and price
Market cap$149M$792M
Share price$2.60$1.78
Change, 1 year−41.6%19.5%
Change, 5 years−85.8%−62.4%
Beta (5Y)1.710.01
Employees22681
StockData Score
Total score8 (better)5
Valuation score3 (better)0
Growth score11
Performance score22
Health score22
Dividend score00
Valuation
P/S5.8× (better)19.1×
P/B1.2× (better)4.5×
FCF yield−54.8%–
Fair value$3.58$0.950
Margin of safety27.4% (better)−87.4%
Growth
Revenue growth (TTM)–−29.0%
Revenue growth, 5Y average−10.3%15.7% (better)
Net income growth (TTM)−210%–
Profitability
Gross margin67.1%99.1% (better)
Operating margin−328%−131% (better)
Net margin−246%−147% (better)
FCF margin−319%–
Return on equity−43.1%−40.2% (better)
Return on invested capital–−163%
Financial health
Debt / equity0.12 (better)0.29
Interest coverage−25.3×–
Current ratio6.6313.37 (better)
Altman Z-score−4.80 (better)−4.87
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions77.9%81.9%
Held by insiders12.3%–
Insider net buying, 12 months−$3.5M$2.8M (better)
Short interest, % of float33.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.